Skip to main content
SpringerLink
Log in

The Neurofibromatoses

  • Chapter
Molecular Pathology in Clinical Practice

  • 1936 Accesses

Abstract

Neurofibromatosis type 1 and neurofibromatosis type 2 are two distinct genetic disorders that predispose to the development of tumors primarily of the nervous system (Table 21-1).1 A recently recognized third form of neurofibromatosis, known as schwannomatosis,2 is not included in this review, as molecular genetic testing is not available for this disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Friedman JM, Butmann DH, MacCollin M, Riccardi VM, eds. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 3rd ed. Baltimore: Johns Hopkins University Press; 1999.

    Google Scholar 

  2. MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64:1838–1845.

    Article  PubMed  CAS  Google Scholar 

  3. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002;17:548–554.

    PubMed  CAS  Google Scholar 

  4. Friedman JM. Neurofibromatosis 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington; 1997–2005. Available at: http://www.genetests.org. Accessed October 20, 2005. Updated October 5, 2004.

    Google Scholar 

  5. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105 (pt 1):608–614.

    Article  PubMed  CAS  Google Scholar 

  6. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311–314.

    Article  PubMed  CAS  Google Scholar 

  7. Stephens K. Neurofibromatosis 1. In: Lupski JR, Stankiewicz P, eds. Genomic Disorders: The Genomic Basis of Genetic Disease. Trenton, NJ: Humana Press; 2006, pp. 207–219.

    Google Scholar 

  8. Dasgupta B, Gutmann DH. Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev. 2003;13:20–27.

    Article  PubMed  CAS  Google Scholar 

  9. De Raedt T, Brems H, Wolkenstein P, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72:1288–1292.

    Article  PubMed  Google Scholar 

  10. Spiegel M, Oexle K, Horn D, et al. Childhood overgrowth in patients with common NF1 microdeletions. Eur J Hum Genet. 2005;13:883–888.

    Article  PubMed  CAS  Google Scholar 

  11. Dorschner MO, Sybert VP, weaver M, Pletcher BA, Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet. 2000;9:35–46.

    Article  PubMed  CAS  Google Scholar 

  12. Gutmann DH, James CD, Poyhonen M, et al. Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1. Neurology. 2003;61:1397–1400.

    PubMed  CAS  Google Scholar 

  13. Venturin M, Guarnieri P, natacci F, et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet. 2004;41:35–41.

    Article  PubMed  CAS  Google Scholar 

  14. Kehrer-Sawatzki H, Kluwe L, Funsterer C, Mautner VF. Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCRmediated 2-Mb deletion in 17q11.2. Hum Genet. 2005;116:466–475.

    Article  PubMed  CAS  Google Scholar 

  15. L’Azaro C, Gaona A, Lynch M, Kruyer H, Ravella A, Estivill X. molecular characterization of the breakpoints of a 12-kb deletion in the NF1 gene in a family showing germ-line mosaicism. Am J Hum Genet. 1995;57:1044–1049.

    CAS  Google Scholar 

  16. Kehrer-Sawatzki H, Kluwe L, Sandig C, et al. High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. Am J Hum Genet. 2004;75:410–423.

    Article  PubMed  CAS  Google Scholar 

  17. Ruggieri M, Huson SM. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology. 2001;56:1433–1443.

    PubMed  CAS  Google Scholar 

  18. Leppig KA, Viskochil D, Neil S, et al. The detection of contiguous gene deletions at the neurofibromatosis 1 locus with fluorescence in situ hybridization. Cytogenet Cell Genet. 1996;72:95–98.

    Article  PubMed  CAS  Google Scholar 

  19. Lopez-Correa C, Dorschner M, Brems H, et al. Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet. 2001;10:1387–1392.

    Article  PubMed  CAS  Google Scholar 

  20. Mantripragada KK, Thuresson AC, Piotrowski A, et al. Identification of novel deletion breakpoints bordered by segmental duplications in the NF1 locus using high-resolution array-CGH. J Med Genet. 2006;43:28–38.

    Article  PubMed  CAS  Google Scholar 

  21. Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000;15:541–555.

    Article  PubMed  CAS  Google Scholar 

  22. Fahsold R, Hoffmeyer S, Mischung C, et al. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet. 2000;66:790–818.

    Article  PubMed  CAS  Google Scholar 

  23. Mattocks C, Baralle D, Tarpey P, Ffrench-Constant C, Bobrow M, Whittaker J. Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain. J Med Genet. 2004;41:e48.

    Article  PubMed  CAS  Google Scholar 

  24. Han SS, Cooper DN, Upadhyaya MN. Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 ( NF1) gene. Hum Genet. 2001;109:487–497.

    Article  PubMed  CAS  Google Scholar 

  25. De Luca A, Buccino A, Gianni D, et al. NF1 gene analysis based on DHPLC. Hum Mutat. 2003;21:171–172.

    Article  PubMed  CAS  Google Scholar 

  26. Gite S, Lim M, Carlson R, Olejnik J, Zehnbauer B, Rothschild K. A high-throughput nonisotopic protein truncation test. Nat Biotechnol. 2003;21:194–197.

    Article  PubMed  CAS  Google Scholar 

  27. Klose A, Peters H, Hoffmeyer S, et al. Two independent mutations in a family with neurofibromatosis type 1 (NF1). Am J Med Genet. 1999;83:6–12.

    Article  PubMed  CAS  Google Scholar 

  28. Wimmer K, Eckart M, Rehder H, Fonatsch C. Illegitimate splicing of the NF1 gene in healthy individuals mimics mutation-induced splicing alterations in NF1 patients. Hum Genet. 2000;106:311–313.

    Article  PubMed  CAS  Google Scholar 

  29. Ars E, Serra E, de la Luna S, Estivill X, Lazaro C. Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA. Nucleic Acids Res. 2000;28:1307–1312.

    Article  PubMed  CAS  Google Scholar 

  30. Li Y, O’Connell P, Breidenbach HH, et al. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics. 1995;25:9–18.

    Article  PubMed  CAS  Google Scholar 

  31. Gervasini C, Bentivegna A, Venturin M, Corrado L, Larizza L, Riva P. Tandem duplication of the NF1 gene detected by high-resolution FISH in the 17q11.2 region. Hum Genet. 2002;110:314–321.

    Article  PubMed  CAS  Google Scholar 

  32. Kehrer-Sawatzki H, Messiaen L. Interphase FISH, the structure of reciprocal translocation chromosomes and physical mapping studies rule out the duplication of the NF1 gene at 17q11.2. A reply. Hum Genet. 2003;113:188–190.

    PubMed  Google Scholar 

  33. Yu H, Zhao X, Su B, et al. Expression of NF1 pseudogenes. Hum Mutat. 2005;26:487–488.

    Article  PubMed  CAS  Google Scholar 

  34. Thomson SA, Fishbein L, Wallace MR. NF1 mutations and molecular testing. J Child Neurol. 2002;17:555–561; discussion 71–72, 646–651.

    PubMed  Google Scholar 

  35. Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics. 2005;36:21–34.

    Article  PubMed  CAS  Google Scholar 

  36. Baser ME, Evans R, Gareth D, Gutmann DH. Neurofibromatosis 2. Curr Opin Neurol. 2003;16:27–33.

    Article  PubMed  Google Scholar 

  37. Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. J Med Genet. 2000;37:897–904.

    Article  PubMed  CAS  Google Scholar 

  38. Evans DG. Neurofibromatosis 2. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Seattle: University of Washington, 1997–2005. Available at: http://www.genetests.org. Accessed October 20, 2005. Updated April 6, 2004.

    Google Scholar 

  39. Baser ME, Kuramoto L, Joe H, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004;75:231–239.

    Article  PubMed  CAS  Google Scholar 

  40. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59:1759–1765.

    Article  PubMed  CAS  Google Scholar 

  41. Evans DG, baser ME, O’Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19:5–12.

    Article  PubMed  CAS  Google Scholar 

  42. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis— the NF2 tumor suppressor, merlin. Genes Dev. 2005;19:2265–2277.

    Article  PubMed  CAS  Google Scholar 

  43. Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109–114.

    Article  PubMed  CAS  Google Scholar 

  44. Abou-Sleiman PM, Apessos A, Harper JC, Serhal P, Winston RM, Delhanty JD. First application of preimplantation genetic diagnosis to neurofibromatosis type 2 (NF2). Prenat Diagn. 2002;22:519–524.

    Article  PubMed  CAS  Google Scholar 

  45. Baser ME, Kuramoto L, Woods R, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet. 2005;42:540–546.

    Article  PubMed  CAS  Google Scholar 

  46. Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59:529–539.

    PubMed  CAS  Google Scholar 

  47. Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/ phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998;35:450–455.

    PubMed  CAS  Google Scholar 

  48. Kluwe L, MacCollin M, Tatagiba M, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J MedGenet. 1998;77:228–233.

    Article  CAS  Google Scholar 

  49. Sestini R, Vivarelli R, Balestri P, Ammannati F, Montali E, Papi L. Neurofibromatosis type 2 attributable to gonosomal mosaicism in a clinically normal mother, and identification of seven novel mutations in the NF2 gene. Hum Genet. 2000;107:366–371.

    Article  PubMed  CAS  Google Scholar 

  50. Wallace AJ, Watson CJ, Oward E, Evans DG, Elles RG. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. Genet Test. 2004;8:368–380.

    Article  PubMed  CAS  Google Scholar 

  51. Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet. 1998;7:2051–2055.

    Article  PubMed  CAS  Google Scholar 

  52. Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumorprone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet. 1998;63:727–736.

    Article  PubMed  CAS  Google Scholar 

  53. Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet. 2003;40:459–463.

    Article  PubMed  CAS  Google Scholar 

  54. Kluwe L, Friedrich RE, Tatagiba M, Mautner VF. Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med. 2002;4:27–30.

    Article  PubMed  Google Scholar 

  55. Kluwe L, Nygren AO, Errami A, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005;42:384–391.

    Article  PubMed  CAS  Google Scholar 

  56. Diebold R, Bartelt-Kirbach B, Evans DG, Kaufmann D, Hanemann CO. Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction. J Mol Diagn. 2005;7:97–104.

    PubMed  CAS  Google Scholar 

  57. Buckley PG, Mantripragada KK, Benetkiewicz M, et al. A fullcoverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet. 2002;11:3221–3229.

    Article  PubMed  CAS  Google Scholar 

  58. Stokowski RP, Cox DR. Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet. 2000;66:873–891.

    Article  PubMed  CAS  Google Scholar 

  59. Gutmann DH, Hirbe AC, Haipek CA. Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet. 2001;10:1519–1529.

    Article  PubMed  CAS  Google Scholar 

  60. Ryu CH, Kim SW, Lee KH, et al. The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene. 2005;24:5355–5364.

    Article  PubMed  CAS  Google Scholar 

  61. Bijlsma EK, Wallace AJ, Evans DG. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J MedGenet. 1997;34:934–936.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and of Laboratory Medicine, USA

    Karen Stephens PhD (Research Professor and Co-Director)

  2. Genetics Laboratory, University of Washington, Medical Genetics, Seattle, WA, 98195, USA

    Karen Stephens PhD (Research Professor and Co-Director)

Authors
  1. Karen Stephens PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, 10021, USA

    Debra G. B. Leonard MD, PhD (Professor and Vice Chair for Laboratory Medicine) (Professor and Vice Chair for Laboratory Medicine)

  2. Hematology, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA

    Adam Bagg MD (Director) (Director)

  3. Department of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA, 30322, USA

    Angela M. Caliendo MD, PhD (Vice Chair and Associate Professor) (Vice Chair and Associate Professor)

  4. Northwestern University Feinberg School of Medicine, Evanston, IL, 60201

    Karen L. Kaul MD, PhD (Professor) (Professor)

  5. Department of Pathology and Laboratory Medicine, Evanston Northwestern Healthcare, Evanston, IL, 60201, USA

    Karen L. Kaul MD, PhD (Professor) (Professor)

  6. Molecular Pathology Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, PA, 19104, USA

    Vivianna M. Van Deerlin MD, PhD (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Stephens, K. (2007). The Neurofibromatoses. In: Leonard, D.G.B., Bagg, A., Caliendo, A.M., Kaul, K.L., Van Deerlin, V.M. (eds) Molecular Pathology in Clinical Practice. Springer, New York, NY. https://doi.org/10.1007/978-0-387-33227-7_21

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-33227-7_21

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33226-0

  • Online ISBN: 978-0-387-33227-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation